Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06117397
Other study ID # 00000462
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date June 14, 2024
Est. completion date December 1, 2025

Study information

Verified date May 2024
Source University of Massachusetts, Worcester
Contact Kimberly Yonkers, MD
Phone 2034945055
Email kimberly.yonkers@umassmemorial.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Development and preliminary testing of a text messaging intervention that will reduce the risk of a major depressive episode and worsening depressive symptoms in perinatal individuals. The system will screen pregnant individuals, send tailored text messages with links to enhanced content, and will include a peer chat function.This accessible text platform will leverage both the ease of use inherent in text messages and the power of enhanced content drawn evidence from based behavioral interventions (Interpersonal Therapy).


Description:

About 1 in 7 pregnant individuals experience depression, with roughly the same number facing this devastating illness after delivery. The downstream effects of perinatal depression adds to its toll with increased risk of preterm birth; impairments in maternal-child attachment; adverse effects on infant development; and decreased breastfeeding initiation/duration. The US Preventative Services Task Force finds that some major depressive episodes (MDEs) can be averted with counseling strategies that employ principles from interpersonal therapy (IPT). They also observe the value of peer support, which can decrease perinatal depression. A possible shared mechanism for these interventions is enhancement of self-efficacy, which is critical in the setting of stressful events such as pregnancy and parenting. However, practical implementation of interventions to reduce depression risk is challenging. Reproductive health providers have limited time and training to deliver depression prevention programs. As well, perinatal individuals may not appreciate the need to participate in a prevention program or have difficulty finding or affording providers of behavioral interventions. Technology can assist with these challenges by providing education, support and therapeutic interventions to perinatal individuals. Unlike web-based applications (apps), text messaging interventions (TMIs) can proactively deliver health information and messages, even to those with limited motivation to engage in preventative interventions. Mobile phone use has exploded with >95% of pregnant individuals (including >85% of the minority population) reporting use of a mobile phone to communicate via short text messages. TMIs can also screen perinatal individuals for depression outside the general medical setting and provide general peer support. With end-user input throughout the process, the investigators will build a multi-component TMI (called Text4Moms) that screens and triages perinatal individuals for risk of a MDE. This system will draw content from IPT; it will send tailored text messages with links to relevant video content to perinatal individuals at risk for a depressive episode. An on-demand secure chat function staffed by a peer with lived experience will complement the text messages for enhanced support. The system will include pre-populated content for peers to cut and paste into text messages for participants, which will support peers and decrease their training burden. This system leverages some of the best components of an app (video, tailoring, chat) into a common and user-friendly text messaging platform. After development, the investigators will conduct a pilot randomized trial to test the ability of the TMI to enhance the target of self-efficacy and decrease depressive symptoms and risk of a MDE. The investigators will query Research Domain Criteria (RDOC) constructs of "loss" and "threat," and will evaluate preliminary effectiveness and implementation (assessment of feasibility, acceptability, use and benefit of the peer chat feature) through a pilot randomized clinical trial.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 40
Est. completion date December 1, 2025
Est. primary completion date December 1, 2025
Accepts healthy volunteers No
Gender Female
Age group 16 Years to 45 Years
Eligibility Inclusion Criteria: - English speaking - "At risk" as determined by an Edinburgh Postnatal Depression Scale score of at least 9, or an average score >3 on the 6-item Medical Outcomes Social Support Survey or history of depression in pregnancy or postpartum depression - At least age 16 - Are willing and able to provide informed consent - Are willing to use a smart phone to receive texts Exclusion Criteria: - In a major depressive episode - Planning on terminating pregnancy - Have panic disorder or substance use disorder - Currently in behavioral health care treatment - Blind individuals - Permanently living in an institutional setting

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Text Messaging Intervention
A text messaging intervention that includes enhanced content such as tailoring, video links and a chat function

Locations

Country Name City State
United States UMass Chan Medical School Worcester Massachusetts

Sponsors (4)

Lead Sponsor Collaborator
University of Massachusetts, Worcester Michigan State University, Worcester Polytechnic Institute, Yale University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Edinburgh Prenatal Depression Scale 10-item continuous measure of depression. Self-report that will be administered by computer. Will be administered three times (for pre-pilot administered at screening, 2 weeks, and 4 weeks; for pilot administered at screening, 4 weeks, and 8 weeks). Items are scored 0-3, with a maximum score of 30. Higher scores show increased severity. Week 4 for pre-pilot and week 8 for pilot, adjusted for baseline
Primary General Self Efficacy Scale 10 item measure of self efficacy. Items are scored 1-4, with scores ranging between 10 and 40. A higher score indicates more self-efficacy. Will be administered three times (for pre-pilot administered at baseline, 2 weeks, and 4 weeks; for pilot administered at baseline, 4 weeks, and 8 weeks). Week 4 for pre-pilot and week 8 for pilot, adjusted for baseline
Primary System Usability Scale 10 items rated on a 1-5 scale, with scores ranging from 0-100, with a higher score indicating greater acceptability. Will be administered one times (for pre-pilot administered at 4 weeks; for pilot administered at 8 weeks). Week 4 for pre-pilot and week 8 for pilot, adjusted for baseline
Primary Patient engagement with text messages Percentage of participants opening >80% of text messages and clicking on >30% of links to enhanced content. 0-8 weeks
Primary Patient engagement with chat Percentage of participants engaging with chat and endorsing 4 out of 5 on its utility. 0-8 weeks
Secondary Diagnosis of a major depressive episode Diagnosis of a major depressive episode using the PHQ-9, the Major Depressive Disorder module of the full PHQ. Will be administered three times (for pre-pilot administered at screening, 2 weeks, and 4 weeks; for pilot administered at screening, 4 weeks, and 8 weeks). Week 4 for pre-pilot and week 8 for pilot, adjusted for baseline
Secondary User Engagement Scale 12 items rated on a 1-5 scale, with scores ranging from 10-50, with higher scores indicating greater acceptability, with an average score of 80.3. Will be administered one time (for pre-pilot administered at 4 weeks; for pilot administered at 8 weeks). Week 4 for pre-pilot and week 8 for pilot, adjusted for baseline
Secondary Perlin Mastery Scale 7 items scaled on a 1-4 scale, with scores ranging from 7-28. Low scores indicate low mastery. Will be administered one time at baseline. Week 4 for pre-pilot and week 8 for pilot, adjusted for baseline
See also
  Status Clinical Trial Phase
Completed NCT03256162 - Ketamine as an Adjunctive Therapy for Major Depression Phase 1
Completed NCT01944293 - Ketamine for Suicidality in Bipolar Depression Phase 1/Phase 2
Recruiting NCT01441505 - A Study of Ketamine as an Antidepressant Phase 2
Active, not recruiting NCT03487926 - Microglial Activation in Inflammatory Bowel Disease
Recruiting NCT04939649 - Ketamine as an Adjunctive Therapy for Major Depression (2) Phase 3
Recruiting NCT05028738 - Patient-oriented Randomized Pragmatic Feasibility Trial With rTMS in Depression and Anxiety N/A
Recruiting NCT03646058 - Add-on Buprenorphine at Analgesic Doses for the Treatment of Severe Suicidal Ideas During a Major Depressive Episode Phase 3
Completed NCT03735576 - Cognitive Behavioural Therapy for the Treatment of Late Life Depression N/A
Recruiting NCT04999553 - Left vs. Right Non-Inferiority Trial N/A
Completed NCT03716869 - Universal vs. Targeted School Screening for Adolescent Major Depressive Disorder N/A
Recruiting NCT02824081 - Neuroinflammation, Serotonin, Impulsivity and Suicide N/A
Terminated NCT01099592 - Antidepressants to Promote Recovery of Cardiac Patients Suffering From Depression Phase 4
Completed NCT03752853 - Stress Systems and Psychotherapy in Depression N/A
Recruiting NCT04480918 - University of Iowa Interventional Psychiatry Service Patient Registry
Recruiting NCT04130958 - Circuit-Based Approach to Suicide: Biomarkers, Predictors, and Novel Therapeutics N/A
Completed NCT03190772 - The Role of Expectations in the Pharmacological Treatment of Depression - An Experimental Investigation N/A
Recruiting NCT04832750 - Depression-Reduction by Accelerated Personalized NeuroModulation and Its Effects on Sleep
Terminated NCT02839798 - NeoSync TMS Treatment for Bipolar I Depression Phase 2
Completed NCT00852592 - Light Therapy for Bipolar Disorder. Efficacy of Light Therapy for Bipolar Depression: A Randomized Controlled Trial Phase 3
Terminated NCT05063604 - Antidepressant Efficacy of Psychotherapy and Citalopram in Patients With Breast Cancer and Major Depression Phase 2